Looking Into Certara’s Return On Capital Employed

According to Benzinga Pro data Certara (NASDAQ:CERT) posted a 85.2% decrease in earnings from Q4. Sales, however, increased…

According to Benzinga Pro data Certara (NASDAQ:CERT) posted a 85.2% decrease in earnings from Q4. Sales, however, increased by 4.23% over the previous quarter to $90.30 million. Despite the increase in sales this quarter, the decrease in earnings may suggest Certara is not utilizing their capital as effectively as possible. Certara reached earnings of $9.17 million and sales of $86.63 million in Q4.

What Is Return On Capital Employed?

Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company’s ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROCE suggests the opposite. In Q1, Certara posted an ROCE of 0.0%.

Keep in mind, while ROCE is a good measure of a company’s recent performance, it is not a highly reliable predictor of a company’s earnings or sales in the near future.

ROCE is a powerful metric for comparing the effectiveness of capital allocation for similar companies. A relatively high ROCE shows Certara is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will generally lead to higher returns and, ultimately, earnings per share (EPS) growth.

For Certara, the positive return on capital employed ratio of 0.0% suggests that management is allocating their capital effectively. Effective capital allocation is a positive indicator that a company will achieve more durable success and favorable long-term returns.

Analyst Predictions

Certara reported Q1 earnings per share at $0.12/share, which did not meet analyst predictions of $0.12/share.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

‘Psychedelics-Inspired’ Meds For Depression, Anxiety, Addiction Producer Trims Q1 Net Loss YoY, Increases Cash On Hand

Enveric Biosciences reported on Wednesday financial results for the first quarter of 2024 ended March 31, 2024."We believe the first quarter of 2024 was a highly productive period for Enveric as the company continued to advance the development of the lead neuroplastogen drug candidate, EB-003, in preparation for an investigational new drug (IND) application and the expected initiation of a planned clinical development program," Joseph Tucker, Ph.D., director and CEO of Enveric, said. "EB-003 was designed specifically to address this major safety profile deficiency in the first-generation psychedelic approach to treating neuropsychiatric illness, and we are excited to advance its development."

ENVB

Read More

DarioHealth Earnings Preview

DarioHealth (NASDAQ:DRIO) is set to give its latest quarterly earnings report on Monday, 2022-11-14. Here's what investors need to know before the announcement. Analysts estimate that DarioHealth will report an earnings per share (EPS) of $-0.76.

DRIO